Protein degradation-focused Lycia Therapeutics launches with $50 million from Versant
Tuesday, June 9, 2020 - 07:10
in Biology & Nature
Using technology from chemical biologist Carolyn Bertozzi's lab, the firm wants to develop drugs that can break down extracelluar proteins